# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-126767
Filing Date
2024-11-14
Accepted
2024-11-14 08:30:40
Documents
76
Period of Report
2024-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | cadl-20240930.htm iXBRL | 10-Q | 2362909
2 | EX-31.1 | cadl-ex31_1.htm | EX-31.1 | 15130
3 | EX-31.2 | cadl-ex31_2.htm | EX-31.2 | 15142
4 | EX-32.1 | cadl-ex32_1.htm | EX-32.1 | 8436
5 | EX-32.2 | cadl-ex32_2.htm | EX-32.2 | 8833
| Complete submission text file | 0000950170-24-126767.txt |  | 7905198

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | cadl-20240930.xsd | EX-101.SCH | 1090977
79 | EXTRACTED XBRL INSTANCE DOCUMENT | cadl-20240930_htm.xml | XML | 1056877

Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 241457384
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)